Skip to content

Automated Microscopy Evaluation Study

Clinical Evaluation of Automated Microscope Solutions for Malaria Diagnosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04558515
Acronym
AutoMic
Enrollment
190
Registered
2020-09-22
Start date
2020-02-01
Completion date
2021-12-31
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Brief summary

Since the introduction of Giemsa stain in 1904 until today, malaria microscopy has been the standard of practice for malaria diagnosis. However, microscopic detection of malaria parasites is labour-intensive, time-consuming and expertise-demanding. Moreover, the slide interpretation is highly dependent on the staining technique and the technician's expertise. To address these, multiple organisations have developed next generation microscopes to move towards a next generation microscope that can improve slide preparation, interpretation or data collection, or a combination of these features. In this study, a prospective evaluation of miLab™ and other next generation automated microscope solutions as well as a malaria rapid diagnostic test (RDT) reader app will be performed in malaria-endemic countries to assess their clinical performance for detection of malaria clinical cases at POC.

Interventions

DIAGNOSTIC_TESTNovel malaria diagnostics & tools

Next generation microscopy tools for malaria diagnosis and medical applications

Sponsors

Foundation for Innovative New Diagnostics, Switzerland
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 5 years or older * Malaria status (positive or negative) established by microscopy at the health facility, where the patient is presenting * Freely agreeing to participate by signing an informed consent form (adults aged 18 and older and parent/legal guardian of a child) and providing assent (children aged 13-17) * Willing to provide finger prick blood sample at enrollment

Exclusion criteria

* Having received antimalarial treatment during the preceding four-week period * Presence of symptoms and signs of severe disease and/or central nervous system infections, as defined by WHO guidelines

Design outcomes

Primary

MeasureTime frameDescription
Concordanceup to 6 monthsPoint estimate with 95% confidence intervals of the percentage agreement in interpreting malaria diagnostics between the app and visual reading
Clinical performance assessmentup to 6 monthsPoint estimates of clinical performance characteristics with 95% confidence intervals (sensitivity, specificity) of next generation microscopy tools using nPCR as the reference test for the detection of malaria clinical cases

Countries

Sudan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026